Results 181 to 190 of about 20,698 (251)

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. [PDF]

Nutr Clin Pract
Singhani V, Ehsan M, Valencia S, Nadeem A, Moazzam E, Butsch WS, Garg S.   +6 more
europepmc   +1 more source

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.
Hussain Salim, Shaheer Qureshi, Gaurav S. Gulsin, Habib R. Khan, Saad Ahmed Waqas, Gerry P. McCann, Amit Garg, Mohammed Shurrab, Kamlesh Khunti, Muhammad Rashid   +9 more
wiley   +1 more source

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice. [PDF]

Endocrinol Diabetes Metab
Sawada M, Nakanishi N, Aihara M, Ohkuma K, Hamano S, Sakurai Y, Sekine R, Usami S, Yamauchi T, Kubota N.   +9 more
europepmc   +1 more source

Trends in GLP‐1‐Based Therapy Use Before and After Pregnancy

Diabetes, Obesity and Metabolism, EarlyView.
Nansi S. Boghossian, Lauren McAbee, Antonio F. Saad, Maged M. Costantine, Marwan Ma'ayeh, Joseph A. Ewing   +5 more
wiley   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source

Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol. [PDF]

Obes Sci Pract
Katz JM, Gearhardt AN, Griauzde DH.
europepmc   +1 more source

Longitudinal Changes in Body Composition, Adaptive Thermogenesis, and Muscle Strength in Patients with Obesity Treated with Semaglutide. [PDF]

Obes Facts
Filippi-Arriaga F, Comas M, Prats A, Juan A, Vidal E, Costa P, Flores V, Oliver-Vila C, Fidilio E, Ciudin A.   +9 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Luke A. Ephraums, Edward R. Mignone, Kylie Lange, Ashlee Routley, Judith Morton, Emily Hopkins, Sally Chapman, Lucia Gagliardi, Michael Horowitz, Mahesh M. Umapathysivam   +9 more
wiley   +1 more source

Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Obesity is a complication of childhood craniopharyngioma that remains difficult to treat. We investigated whether semaglutide was associated with a decrease in BMI among adolescents with craniopharyngioma‐related obesity. Material and Methods This multicentre retrospective study included 20 patients < 18 years old with craniopharyngioma ...
Joanne Dornberger, Pascal Barat, Karine Aouchiche, Kevin Perge, Carine Villanueva, Sarah Castets, Natacha Bouhours‐Nouet, Aurelie Donzeau, Lucie Levaillant, Cecile Teinturier, Rachel Reynaud, Ahlam Azar‐Kolakez, Laetitia Martinerie, Dulanjalee Kariyawasam, Regis Coutant   +14 more
wiley   +1 more source

The Evolution of Medications for Obesity Management. [PDF]

JGH Open
Gill J, Sumithran P.
europepmc   +1 more source